Zobrazeno 1 - 10
of 37
pro vyhledávání: '"Toyoko, Kikuchi"'
Autor:
Haider, Asifa S., Cohen, Jules, Fei, Ji, Zaba, Lisa C., Cardinale, Irma, Toyoko, Kikuchi, Ott, Jurg, Krueger, James G. *
Publikováno v:
In Journal of Investigative Dermatology March 2008 128(3):655-666
Autor:
Leanne M Johnson-Huang, Cara A Pensabene, Kejal R Shah, Katherine C Pierson, Toyoko Kikuchi, Tim Lentini, Patricia Gilleaudeau, Mary Sullivan-Whalen, Inna Cueto, Artemis Khatcherian, Luke A Hyder, Mayte Suárez-Fariñas, James G Krueger, Michelle A Lowes
Publikováno v:
PLoS ONE, Vol 7, Iss 2, p e30308 (2012)
UnlabelledTo understand the development of new psoriasis lesions, we studied a group of moderate-to-severe psoriasis patients who experienced a relapse after ceasing efalizumab (anti-CD11a, Raptiva, Genentech). There were increased CD3(+) T cells, ne
Externí odkaz:
https://doaj.org/article/3578f6aa939e4e8fb1132dc90435b9aa
Autor:
Yulia Vugmeyster, Francesca Chamian, Edmund Lee, Toyoko Kikuchi, Wolfgang Dummer, Kathy Howell, Michelle A. Lowes, Emma Guttman-Yassky, James G. Krueger, Sarah C. Bodary, Brisdell Hunte, Patricia Gilleaudeau, Mark Kagen
Publikováno v:
Journal of Investigative Dermatology. 128(5):1182-1191
Efalizumab (anti-CD11a) interferes with LFA-1/ICAM-1 binding and inhibits several key steps in psoriasis pathogenesis. This study characterizes the effects of efalizumab on T-cell activation responses and expression of surface markers on human circul
Autor:
Asifa Haider, Irma Cardinale, Kamruz Darabi, Raj Bandaru, Michelle A. Lowes, James G. Krueger, Inna Novitskaya, Francesca Chamian, Humphrey Gardner, Patricia Gilleaudeau, Mary S. Whalen, Toyoko Kikuchi
Publikováno v:
The Journal of Immunology. 178:7442-7449
Alefacept is an LFA3-Ig fusion protein that binds to CD2 and is thought to inhibit T cell activation by antagonism of CD2 signaling or by lysis of CD2+ cells. Alefacept is potential future therapeutic for organ transplant recipients or graft-vs-host
Autor:
Sarah C. Bodary, James G. Krueger, Patricia Gilleaudeau, Yulia Vugmeyster, Michelle A. Lowes, Francesca Chamian, Edmund Lee, Kathy Howell, Toyoko Kikuchi, Wolfgang Dummer, Mark Kagen
Publikováno v:
Clinical Immunology. 113:38-46
Therapeutic administration of efalizumab, a humanized antibody to CD11a, induces a marked but reversible increase of peripheral lymphocytes in psoriasis patients. In this study, 13 patients were treated with 12 weekly subcutaneous doses (2 mg/kg/week
Publikováno v:
Clinical Immunology. 102:225-236
Sarcoidosis, a chronic granulomatous disease of unknown etiology, is treated with immune suppressive drugs such as corticosteroids. Sarcoidosis patients have been reported to benefit clinically from treatment with thalidomide. We administered thalido
Autor:
James G. Krueger, Brian V. Jegasothy, Judith R. Abrams, Toyoko Kikuchi, Michael J. Brown, Sewon Kang, Cynthia Guzzo, Elizabeth Hayes, Peter S. Linsley, Susan Kelley, Mark Lebwohl
Publikováno v:
The Journal of Experimental Medicine
Efficient T cell activation is dependent on the intimate contact between antigen-presenting cells (APCs) and T cells. The engagement of the B7 family of molecules on APCs with CD28 and CD152 (cytotoxic T lymphocyte–associated antigen 4 [CTLA-4]) re
Autor:
Andrew J. Dorner, William L. Trepicchio, Judith L. Bliss, Toyoko Kikuchi, James G. Krueger, Ian B. Walters, Maki Ozawa, Patricia Gilleaudeau, Ullrich S. Schwertschlag
Publikováno v:
Journal of Clinical Investigation. 104:1527-1537
Psoriasis is a chronic inflammatory skin disease in which epidermal hyperplasia results from skin infiltration by type I T lymphocytes and release of associated cytokines. A multifunctional cytokine, rhIL-11, modulates macrophage and type I T-lymphoc
Publikováno v:
Journal of Investigative Dermatology. 113(5):752-759
Psoriasis vulgaris is a skin disease potentially mediated by pro-inflammatory cytokines produced by type 1 lesional T cells. The capability of individual T cells to produce these cytokines in lesional skin is not known. In this study we measured the
Autor:
Toyoko Kikuchi, Maki Ozawa, Irma Cardinale, James G. Krueger, Todd R. Coven, Lauren H. Burack, Katalin Ferenczi, Lisa M. Austin
Publikováno v:
The Journal of Experimental Medicine
Narrow-band (312 nm) ultraviolet B light (UVB) is a new form of therapy for psoriasis, but its mechanism of action is unknown. In a bilateral comparison clinical study, daily exposure of psoriatic plaques to broad-band UVB (290–320 nm) or 312-nm UV